Company Focus on Transformational MilestonesVANCOUVER, BC / ACCESSWIRE / November 28, 2022 / RepliCel Life Sciences Inc. (TSXV:RP)(OTC PINK:REPCF) ("RepliCel" or the "Company"), a company developing next-generation
New DermaPrecise patent application and patents granted for tendinopathy and skin rejuvenation technologies in key marketsVANCOUVER, BC / ACCESSWIRE / August 4, 2022 / RepliCel Life Sciences Inc. (OTCPK:REPCF)(TSXV:RP)(FRA:P6P2)
RepliCel Announces Material Patent Milestones in Key Markets streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Independent Testing Performed by Innovacell Demonstrates the DermaPrecise Control Leads to Unparalleled Post-Injection Cell Survival and Viability ConsistencyVANCOUVER, BC / ACCESSWIRE / August 2, 2022
DermaPrecise(TM) Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.